Ophthalmology Times covers nasal neurostimulator

Dry-eye treatment usually means adding something from the outside — artificial tears, anti-inflammatory drops, punctal plugs, warm compresses. This device tried the opposite move. Instead of pouring more fluid onto the eye, it tried to make the eye’s own tear system switch back on. That was the idea behind Allergan’s Oculeve intranasal tear neurostimulator, the device discussed in Ophthalmology Times in March 2017. (ophthalmologytimes.com) ### What was the device, exactly? It was a handheld neurostimulator with a reusable body and soft disposable hydrogel tips that went just inside the nose. The device delivered a small electrical stimulus to sensory nerves in the nasal cavity. Patients could adjust the intensity across five stimulation levels. The basic bet was simple — the nose is wired into the same reflex arc that helps trigger tearing. (ophthalmologytimes.com) ### Why would stimulating the nose make tears? Because tear production is not just a gland problem. It is a circuit problem. The lacrimal functional unit links the ocular surface, corneal nerves, lacrimal gland, and nasal sensory pathways. If you have ever teared up from wasabi or a nasal swab, you have felt the same refle(ophthalmologytimes.com)tears. (ophthalmologytimes.com) ### What did the early study show? The eye-catching number was Schirmer testing. In the randomized controlled trial highlighted in the piece, the stimulated group reached 29.2 mm, compared with 15.5 mm for placebo and 15.3 mm for sham. The trial Ophthalmology Times described enrolled patients with aqueous-deficient dry eye(ophthalmologytimes.com)it is enough to show a real acute tear-production signal. (ophthalmologytimes.com) ### Was this just a one-off signal? Not really. Later reviews pulled together a broader literature base. A 2022 meta-analysis covering 15 published studies and 17 clinical trials, with 901 patients total, found significantly higher Schirmer II scores after intranasal tear neurostimulation, with a pooled mean difference of (ophthalmologytimes.com)e nasolacrimal reflex — held up reasonably well across studies. (link.springer.com) ### Did it help anything besides watery output? Maybe, but this is where the story gets messier. Some studies suggested symptom improvement and even changes in meibomian gland metrics. But dry eye is not one disease with one bottleneck. If the main problem is inflammation, meibomian gland dysfunction, or poor tear-film quality, making more aqueous tears may help without (link.springer.com)nct than a universal replacement for standard dry-eye care. (link.springer.com) ### So why didn’t this become the default? The catch is usability. TrueTear — the commercial version of the intranasal device — did get FDA authorization in 2017, but it was later removed from the market in August 2020. The American Academy of Ophthalmology notes it is no longer available for purchase. That does not mean the mechanism failed. It means a clever physiologi(link.springer.com)g, and commercial traction. (aao.org) ### What replaced it? The field shifted from intranasal electrical stimulation to external nasal stimulation. Olympic Ophthalmics’ iTEAR100, cleared in 2022, stimulates the external nasal nerve from outside the nose and is indicated for temporary use to increase acute tear production in adults. Basically, same broad neurostimulation logic — less invasive form factor. (accessdata.fda.gov) ### Bottom line? The Ophthalmology Times piece captured a real moment in dry-eye treatment — when clinicians started asking whether the better move was not more drops, but better wiring. That idea turned out to be scientifically credible. But product success and physiologic truth are not the same thing. The reflex works. The harder question is which device, in which patients, is practical enough to matter every day. (ophthalmologytimes.com)